Search results for "Venous thromboembolism"
Industry-funded trial finds a direct factor X inhibitor noninferior to a low-molecular-weight heparin for cancer-associated VTE
Edoxaban was associated with a lower rate of recurrent venous thromboembolism (VTE) but a higher rate of major bleeding.
https://immattersacp.org/weekly/archives/2017/12/19/2.htm
19 Dec 2017
Managing DOACs in primary care
Primary care physicians play a crucial role in ongoing anticoagulation management, including educating patients about the signs of venous thromboembolism.
https://immattersacp.org/archives/2022/04/managing-doacs-in-primary-care.htm
1 Apr 2022
Patients with provoked VTE often on anticoagulation longer than recommended
Three variables were associated with receiving anticoagulation for longer than three months after a provoked venous thromboembolism (VTE): direct oral anticoagulant use, history of VTE, and history of myocardial infarction.
https://immattersacp.org/weekly/archives/2022/11/01/4.htm
1 Nov 2022
New warning for testosterone, approval for inhaled insulin
This update covers a revised warning on testosterone products about the risk of venous thromboembolism, and approval of a fast-acting inhaled insulin to treat diabetes in adults.
https://immattersacp.org/archives/2014/09/fda.htm
1 Sep 2014
VTE risk appears lower with transdermal vs. oral hormone replacement therapy
Nested case-control studies using two U.K. primary care databases found that oral hormone replacement therapy was associated with a significantly increased risk for venous thromboembolism (VTE), while transdermal formulations were not.
https://immattersacp.org/weekly/archives/2019/01/15/1.htm
15 Jan 2019
Outcomes of limited cancer screening after unprovoked VTE similar to extensive screening
The overall prevalence of cancer in the 12 months after a diagnosis of venous thromboembolism was 5.2%. While the point prevalence was higher in patients receiving extensive screening than in those receiving limited screening, there was no significant difference at one year.
https://immattersacp.org/weekly/archives/2017/08/22/4.htm
22 Aug 2017
New resource offers pearls for perioperative medicine
A recent book addresses perioperative medicine, including how to be a perioperative consultant, prophylaxis for venous thromboembolism, coexisting medical problems, and common postoperative complications.
https://immattersacp.org/archives/2022/02/new-resource-offers-pearls-for-perioperative-medicine.htm
1 Feb 2022
Apixaban shows superior effectiveness, safety compared to rivaroxaban
For patients with venous thromboembolism, initiation of apixaban was associated with lower rates of recurrence and intracranial and gastrointestinal bleeding than rivaroxaban in a population-based cohort study.
https://immattersacp.org/weekly/archives/2021/12/07/2.htm
7 Dec 2021
Tailoring anticoagulation more of a reality with DOACs
Direct oral anticoagulants have the potential to replace warfarin for the treatment of many patients with venous thromboembolism, but without a need for routine monitoring, good patient selection is key to their use.
https://immattersacp.org/archives/2018/03/tailoring-anticoagulation-more-of-a-reality-with-doacs.htm
1 Mar 2018
DOACs may be safe, effective for VTE prevention in patients with higher weight, BMI
Patients with first-time venous thromboembolism (VTE) who weighed 120 kg or more and had a body mass index (BMI) of 40 kg/m2 or more were not at higher risk for bleeding or recurrent VTE with direct-acting oral anticoagulants (DOACs) versus warfarin.
https://immattersacp.org/weekly/archives/2021/11/09/4.htm
9 Nov 2021